ALL THINGSMEDTECH

Edwards Lifesciences

EW

The global leader in patient-focused innovations for structural heart disease and critical care. Pioneer of transcatheter heart valves (TAVR).

FDA ApprovedCE MarkBreakthrough Device
$72.30
-1.2%
Market Data
Headquarters
Irvine, CA
CEO
Bernard Zovighian
Founded
1958
Employees
19,000+
Sector
Structural Heart
Therapeutic Area
Structural Heart, Critical Care
Stage
Public
Total Funding
Public (NYSE: EW)

Regulatory Pipeline

SAPIEN 3 Ultra RESILIA Valve

PMA · Class III · Jul 2023

Approved

EVOQUE Tricuspid Valve

PMA · Class III · Jan 2024

Breakthrough

PASCAL ACE Repair System

PMA · Class III · Mar 2023

Approved

Funding History

IPO

2000-03-21

$93M

NYSE

Clinical Trials

PROGRESS Tricuspid

Recruiting

Phase III · US, EU

PARTNER 4 TAVR

Active

Phase III · Global

Open Positions

Biomedical Engineer - Valve Design

R&D · Irvine, CA

$120K-$160K+ RSUs
FEABiocompatibilityTAVR
← Back to Directory